Clinical trials
Phase 3 Renal Insufficiency trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
44 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 7 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 1 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 37 |
| Terminated | 4 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Veloxis Pharmaceuticals | 5 |
| Akebia Therapeutics | 4 |
| Humacyte, Inc. | 2 |
| Indiana University | 2 |
| Keryx Biopharmaceuticals | 2 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 |
| OPKO IP Holdings II, Inc. | 2 |
| American Regent, Inc. | 1 |
| Amgen | 1 |
| Amicus Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Renal Insufficiency | 44 |
| Kidney Failure, Chronic | 12 |
| Renal Insufficiency, Chronic | 11 |
| Kidney Diseases | 7 |
| Diabetes Mellitus, Type 2 | 6 |
| Anemia | 5 |
| Heart Failure | 4 |
| Hyperphosphatemia | 4 |
| Anemia, Iron-Deficiency | 2 |
| Hyperparathyroidism | 2 |
Trials
Showing 1 to 25 of 44. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.